pharmaphorum

MARCH 24, 2022

Ann Aerts, head of the Novartis Foundation, tells us about AI4Leprosy, a diagnostic assistant researchers developed that helps healthcare workers detect leprosy with over 90% accuracy using pictures of a patient’s skin lesion. . Leprosy has existed for more than 3,000 years and is the one of the oldest diseases known to humanity. Though a cure is available, 200,000 individuals are still diagnosed with the disease each year. “We’ve managed to reduce the burden of leprosy by 95%

107

107

Outsourcing Pharma

MARCH 24, 2022

The pharmaceutical company's clinical study is intended to examine critical gaps in care for people of color living with moderate to severe plaque psoriasis.

Pharmaceutical Companies 95

Pharmaceutical Companies Pharmaceutical Companies 95

pharmaphorum

MARCH 24, 2022

GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds. There’s a rich history of finding useful medicines from fungi, from the antibiotic penicillin to immune suppressant cyclosporine and cholesterol drug lovastatin.

Compounding 97

Compounding Immunization 97

Outsourcing Pharma

MARCH 24, 2022

The companyâs analysis of clinical research activity in the region shows the conflict will have long-lasting effects that reach beyond the countryâs borders.

59

59

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MARCH 24, 2022

Novartis has been steadily investing in radiopharmaceuticals over the last few years, and one of those deals has just paid off with an FDA approval for Pluvicto, the first targeted radioligand therapy for prostate cancer. Pluvicto (lutetium Lu 177 vipivotide tetraxetan) – formerly known as 177Lu-PSMA-617 – has been cleared in the US for previously-treated patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), a group with limited treatment options.

Chemotherapy 59

Chemotherapy Labelling FDA 59

Pharma Times

MARCH 24, 2022

The platform to build a digital-ready frontline workforce will be available to all NHS and social care staff

62

62

Pharma Times

MARCH 24, 2022

Collaboration will focus on AI analysis of flu progression, immune responses and the development of new vaccines

Immunization 50

Immunization Vaccines 50

pharmaphorum

MARCH 24, 2022

In the latest episode of the pharmaphorum podcast, editor in chief Jonah Comstock speaks with Miruna Sasu, chief strategy officer of COTA and long-time pharma vet– before joining COTA last year, she headed up J&J’s Clinical Trial Feasibility and Advanced Analytics Team and led the Digital Health and Innovation Team at Bristol Myers Squibb.

52

52

Roots Analysis

MARCH 24, 2022

Scientific fields involved in high throughput measurement of biological molecules are referred with the suffix- omics including, transcriptomics, genomics, proteomics and metabolomics. Genomics is the study of genetic material within a cell, and transcriptomics is the study of gene activity in different cells. Likewise, metabolomics refers to the study of byproducts of metabolism.

Compounding 52

Compounding 52